There is no limit to the brazenness of the elite!
There are now AAA rated bonds based on poor people receiving vaccinations! That’s right. Interest payments on these “Vaccine Bonds” are guaranteed by France, Italy, Norway, South Africa, Spain, Sweden and Britain.
Who buys these bonds?
The International Finance Facility for Immunisation says the following about the initial offering in 2006:
The bonds were priced comparably to other sovereign/supranational issuers and were bought by a broad range of investors – both geographically and by investor type – including several central banks, pension funds, fund managers, and insurance companies. Deutsche Bank and Goldman Sachs lead-managed this inaugural bond issue.
Individuals who have supported the IFFIm initiative include His Holiness Pope Benedict XVI; Her Majesty Queen Rania Al-Abdullah of Jordan; Cardinal Renato Raffaele Martino; Archbishop of Canterbury, Dr Rowan Williams; Chief Rabbi, Dr Jonathan Sacks; Iqbal Khan of the Muslim Council of Britain; Ramesh Khalidi of the Hindu Forum; Indrajit Singh OBE of the Sikh Council of Britain as well as Bono and Bob Geldof.
I couldn’t make it up if I tried.
There have also been retail offerings of the “Vaccine Bonds” in Japan in 2008 and 2009.
There are a number of documents on the web site. I’m going to need to take some time to look through this. Check it out for yourself : iff-immunisation.org
12 Responses to “Organization Issuing Bonds Based On Guaranteed Payments For The Vaccination Of Poor Populations”
1. Jacko Says:
April 17th, 2009 at 5:01 am The “elite”, who will never vaccinate themselves or their children, have basically just bet on the thousands, if not millions of deaths that will occur as a result of the mass vaccination programs WHO will dole out in “fear” of the bird-flu or any other “deadly” virus they have developed for mass extermination. Why not make millions of euros or dollars off the dead and dying they will initiate? What a great plan! Where can I buy a bond or two?
You start with the poorest nations because the people are basically uneducated and use religion as their basis of existence. When they start dying off (from the vaccine itself) you can scare the rest of the educated world they had better get vaccinated or else. Dr. Len Horowitz’s books document how AIDS was developed by our military along with Dr. Robert Strecker’s video on the same subject. I went to the law and medical libraries and copied the documents myself that both Drs. cited. It’s all there IN PRINT, in respected medical journals and in the proceedings from Congress!!
Start eating lots of Kim Chee, the Korean fermented cabbage dish as it was documented a couple of years ago to KILL the HI51 bird-flu virus - of course that never got reported in MSM. Start looking for ways to strengthen your immune system through food. Little known info - proteolytic (protein digesting) enzymes completely destroy (digest) any virus and bacteria no matter who makes them. Stock up some of those soon.
________________________________________________________________________________________________
Sanofi : HERE.
Sanofi Aventis Invests 100 Million Euros In New Facility In Mexico To Produce Seasonal and Pandemic Influenza Vaccine
19 Mar 2009
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY), announced the signing of an agreement with the Mexican authorities to build a 100 million euro facility to manufacture influenza vaccine in Mexico.
The announcement was made during a ceremony attended by Felipe Calderon, President of Mexico, and Nicolas Sarkozy, President of France, who was in Mexico City for a State visit.
This facility will be built and operated by sanofi pasteur, the vaccines division of sanofi-Aventis Group, which was represented at the ceremony by Chris Viehbacher, Chief Executive Officer of sanofiaventis. "By building this new facility, sanofi-aventis is proud to contribute to the strengthening of Mexico's health infrastructure and is eager to support Mexico's exemplary commitment to public health through influenza immunization and pandemic readiness", said Chris Viehbacher. "This investment illustrates sanofi-aventis' local approach to global health. This facility will benefit public health in Mexico and the Latin American region, in the context of influenza pandemic preparedness".
The agreement was signed by Birmex' (Laboratorio de Biológicos y Reactivos de México) and sanofi-aventis' representatives in the presence of Dr. José Ángel Córdova Villalobos, Minister of Health of Mexico.
Under the terms of the agreement, sanofi Pasteur will manufacture influenza vaccine in collaboration with Birmex, a Mexican federal vaccine manufacturer. Birmex will perform certain stages of manufacturing and will be responsible for distributing influenza vaccines to the public in Mexico. Sanofi Pasteur is planning to start construction of the new vaccine manufacturing facility within a few weeks. Upon completion within four years, the facility will have a yearly capacity of up to 25 million doses of seasonal influenza vaccine.
The new influenza vaccine plant will be built in Ocoyoacac, where sanofi-aventis already operates a facility. The plant will be designed to switch to pandemic vaccine manufacturing if a human influenza pandemic is declared and a pandemic influenza strain is identified by the World Health Organization (WHO).
As the world leader in research, development and manufacturing of influenza vaccines, sanofi pasteur is working to develop new and improved influenza vaccines to save lives and is actively involved in pandemic preparedness. Over the last five years, sanofi pasteur has been consistently investing in major expansions of its influenza vaccine production capacity in the United States, France, China, and now Mexico. With the production of more than 170 million doses of seasonal influenza vaccine in 2008, sanofi Pasteur confirmed its global influenza vaccine market leadership.
Seasonal influenza overview
Influenza is a disease caused by a highly infectious virus that spreads easily from person to person, primarily when an infected individual coughs or sneezes. According to the World Health Organization (WHO), the average global burden of inter-pandemic influenza may be on the order of 1 billion cases per year, leading to 300,000-500,000 deaths worldwide1. In temperate climate zones, seasonal epidemics typically begin in the late Fall and peak in mid-winter, infecting about 5-15% of the population each season, while In tropical zones the virus can be isolated year-round. The disease can affect all age groups, but rates of infections are highest among young children who spread the virus and are a potential source of infection in older age cohorts, whereas rates of serious illness, complications and death are highest in persons aged 65 years and older, as well as in persons with chronic cardiac or respiratory conditions1. The efficacy of vaccination in reducing the burden of the disease, as well as the economic burden of treating influenza, is well established.
Pandemic Influenza Overview
Influenza is a disease caused by a highly infectious virus that spreads easily from person to person, primarily when an infected individual coughs or sneezes1. An influenza pandemic is a global epidemic of an especially virulent virus, newly infectious for humans, and for which there is no pre-existing immunity.
This is why pandemic strains have such potential to cause severe morbidity and mortality. In an attempt to minimize the impact of a pandemic, many countries are developing national and transnational plans against a possible influenza pandemic situation. For more information on sanofi pasteur and pandemic preparedness, please visit HERE.
About Sanofi Aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2008, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development.
No comments:
Post a Comment